Relay Therapeutics (NasdaqGM:RLAY) plans to move its lead program, zovegalisib, into Phase 3 development for frontline PI3Ka ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results